Colorado PDAB Decisions Highlight Differing State Drug Board Structures

Updated Story How state bills creating prescription drug affordability boards (PDABs) define affordability result in varied scenarios for what could happen as the boards move forward. In Colorado, where the board focuses on affordability for consumers, manufacturers’ assistance programs have played a large role, specifically in determining whether Vertex’s Trikafta and Gilead Sciences’ Genvoya are affordable. Colorado’s PDAB voted that Trikafta, a therapy for cystic fibrosis that costs over $200,000 per patient, is “ not unaffordable ,”...